

EXPRESS MAIL CERTIFICATE

DATE _____ LABEL NO. _____

I HEREBY CERTIFY THAT, ON THE DATE INDICATED ABOVE
THIS PAPER OR FEE WAS DEPOSITED WITH THE U.S. POSTAL SERVICE
& THAT IT WAS ADDRESSED FOR DELIVERY TO THE ASSISTANT COMMISSIONER
OF PATENTS & TRADEMARKS, WASHINGTON, DC 20231 BY "EXPRESS
MAIL POST OFFICE TO ADDRESSEE" SERVICE.

NAME (PRINT)

SIGNATURE

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR
CREDIT ANY EXCESS IN THE FEES DUE WITH THIS
DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

jc973 U.S. PTO
09/903665
07/13/01



6485/16895

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Giancarlo SANTUS ET AL.

Serial No: N/A

Group Art Unit: N/A

Filed: concurrently herewith
(Rule 53(b) Continuation of 08/383,707)

Examiner: N/A

For: THERAPEUTIC COMPOSITIONS FOR INTRANASAL
ADMINISTRATION WHICH INCLUDE KETOROLAC

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a
copy of Form PTO-1449. Copies of previously-disclosed references for the prior art

can be located in the parent applications except for Zia et al. (U.S. Patent No. 6,090,368) which is attached. These documents contain information which the Examiner should consider during examination of the present application.

The present application incorporates a concise explanation of the relevance of each cited reference conforming to the requirements of 37 C.F.R. §1.98(a)(3).

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of

examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,



Adda G. Gogoris
Reg. No. 29,714
Attorney For Applicant(s)

DARBY & DARBY P.C.
805 Third Avenue
New York, NY 10022
(212) 527-7700

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 6485/16895 SERIAL NO: N/A
APPLICANT: Giancarlo SANTUS et al. FILING DATE: concurrently herewith
CONFIRMATION NO: 1001731

JC 973 U.S. PTO
09/903665 07/13/01

U.S. PATENT DOCUMENTS

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>NAME</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>FILING DATE</u>
	1. 4,089,569	May, 1978	Muchowski	514	416	Feb., 1977
	2. 4,478,822	Oct., 1984	Haslam	424	78	May, 1983
	3. 4,778,810	Oct., 1988	Wenig et al.	514	263	Jan., 1987
	4. 4,885,287	Dec., 1989	Hussain	514	159	August, 1988
	5. 4,973,596	Nov., 1990	Cohen	514	354	May, 1988
	6. 6,090,368	July, 2000	Zia et al.	424	45	March, 1998

FOREIGN PATENT DOCUMENTS

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>COUNTRY</u>	<u>CLASS SUBCLASS</u>	<u>TRANSLATION YES</u>	<u>NO</u>
	7. WO 88/04929	7/14/88	PCT	A61K31 52 & 62	English	
	8. WO 90/07333	7/12/90	PCT	A61K31 445	English	

JCG73 U.S. PRO
09/903665

07/13/01

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 6485/16895
APPLICANT: Giancarlo SANTUS et al.SERIAL NO: N/A
FILING DATE: concurrently herewith
CONFIRMATION NO:*EXAMINER
INITIALS**OTHER REFERENCES**
(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)*EXAMINER
INITIALS

9. Mroszczak, E. J., et al., Ketorolac Tromethamine Absorption, Distribution, Metabolism, Excretion, and Pharmacokinetics in Animals and Humans, *Drug Metab. Dispos.*, 15 (5):618-626, 1987
10. Chien, Y.W. and Chang, S.F., Historical Development of Transnasal Systemic Medications; In: *Transnasal Systemic Medications*, edited by Y.W. Chien, Elsevier Science Publishers B.V., Amsterdam, 1985
11. Buckley, M.M.T., *Drugs* 39:86-109, 1990.
12. Yu, D., *Pharmaceutical Research* 5 :457-462, 1988.
13. Rooks, W.H. *Drugs Exptl. Clin. Res.* 11:479-492, 1985.
14. O'Hara, D.A., *Clin. Pharmacol. Ther.* 41:556-561, 1987.
15. Illum, L., *International Journal of Pharmaceutics* 39:189-199, 1987.
16. Morimoto, K., *J. Pharm. Pharmacol.* 37:134-136, 1985.
17. Hirai, S., *International Journal of Pharmaceutics* 9:165-172, 1981.

JC973 U.S. PRO
09/903665

07/13/01

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 6485/16895

SERIAL NO: N/A

APPLICANT: Giancarlo SANTUS et al.

FILING DATE: concurrently herewith
CONFIRMATION NO:***EXAMINER**
INITIALS

18. Pennington, A.K., International Journal of Pharmaceutics 43:221-224, 1988.
19. DePonti, R., Drug Development and Industrial Pharmacy 17:1419-1436, 1991.

EXAMINER: _____

DATE CONSIDERED: _____

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.